Question 1

What is Cumulus Neuroscience?

Accepted Answer

Cumulus Neuroscience is a Entity.

Question 2

How often does Cumulus Neuroscience appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was Cumulus Neuroscience first tracked by Ergen?

Accepted Answer

First tracked on May 28, 2026.

Question 4

When was Cumulus Neuroscience last mentioned in news?

Accepted Answer

Last active on Aug 18, 2026.

Question 5

What is Cumulus Neuroscience's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Cumulus Neuroscience in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Cumulus Neuroscience?

Accepted Answer

Cumulus NeuLogiq ALS FTD Study Published (Aug 18, 2026, 6 articles).

Question 8

How did the "Cumulus NeuLogiq ALS FTD Study Published" event impact Cumulus Neuroscience?

Accepted Answer

Cumulus Neuroscience is the developer of the NeuLogiq platform and the sponsor of the CNS-102 study. The publication in Scientific Reports validates its technology, potentially enhancing its reputation and commercial opportunities in CNS clinical trials.

Question 9

How did the "Delix Zalsupindole Phase 1b Results" event impact Cumulus Neuroscience?

Accepted Answer

Cumulus Neuroscience's NeuLogiq Platform was instrumental in confirming the safety and cognitive function of zalsupindole, validating its platform's utility in neuropsychiatry clinical trials and potentially increasing its partnerships.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.